← Human Trials & Peer-Reviewed Studies
Effects of transdermal nicotine patches on ambulatory ECG monitoring findings: a double-blind study in healthy smokers
Plain-language guide to PMID 8842510 (1996): double-blind randomized controlled trial study of Therapeutic nicotine (patch, non-peptide) in 22 subjects.
Key Facts
- PMID
- 8842510
- Journal
- Cardiovascular drugs and therapy
- Year
- 1996
- Study type
- Randomized Controlled Trial
- Authors
- Khoury Z et al. (6 authors)
- DOI
- 10.1007/BF00823596
- Registered trial
- NCT00775749
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Therapeutic nicotine (patch, non-peptide).
Twenty-two patients in each group completed the trial.
During the treatment period, subjects also received behavioral supportive therapy.
Who Took Part
The study group was 22 subjects.
PubMed indexes the participants as adults and middle-aged adults, both men and women.
The cardiovascular effects and safety of transdermal nicotine patches were assessed in 50 healthy smokers using repeated 48 hour ambulatory electrocardiographic monitoring as a part of a smoking cessation program.
Following baseline measurements, subjects were randomized to active (n = 25) or placebo (n = 25) treatment groups for a period of 2 weeks.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The subjects were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.
As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.
The methods mention a period of 2 weeks.
What Was Measured
PubMed files the paper under topics including Administration, Cutaneous, Blood Pressure, Electrocardiography, Ambulatory, Heart Rate, Nicotine, Smoking and Smoking Cessation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 22 subjects over 2 weeks.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1996 (Cardiovascular drugs and therapy), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.